Synexus continues expansion of clinical trials capability into Hungary

Synexus Clinical Research, the UK-based multinational company specialising in the recruitment and running of late stage clinical trials, has added a clinical trials centre in Hungary to its portfolio of more than 15 hub sites in the UK, Eastern Europe and India.

Through these sites, the company can now access tens of millions of prospects, an increasing proportion of whom are treatment-naïve. Such a wide prospect pool, coupled with Synexus" service at all stages of the trials process, means that pharmaceutical companies can get their products onto the market and into profit faster and more cost effectively, the company says.

The new Synexus hub centre, which was previously known as Diagnostics Units Hungary, is based in Budapest and has been established for some years. The Hungary site will be taking advantage of Synexus" tried and tested capability of recruiting large numbers of patients into late stage clinical trials for the pharma-ceutical industry.

Recognising that patient retention is a critical factor in the success of any clinical trials process, all Synexus-run trials are based at their state-of-the-art, wholly owned medical centres - the so-called hub sites. These hub sites uniformly deliver an excellent patient experience and are attentive to cultural differences, in order to minimise costly patient dropout during the course of a clinical trial. All Synexus hub staff are GCP-trained.

"Through this latest acquisition we can continue to grow our reputation for providing our clients with superior clinical trials, on time while dramatically reducing their costs," said Ian Smith, medical director and founder of Synexus. The company estimates that typically it can save a pharmaceutical company over 80% on set-up and monitoring costs when compared with carrying out the trial through many part time investigators.